IMblaze370 investigated the use of PD-L1 inhibition with atezolizumab (with or without MEK inhibitor cobimetinib) versus monotherapy with the tyrosine kinase inhibitor regorafenib in 363 patients with previously treated irresectable locally advanced or metastatic colorectal cancer, finding no difference in overall survival between groups. Here, MAP2K7 is linked to metastatic colorectal cancer.